Sharma Anjali, Sharma Rohit, Sharma Madhurima, Panadan John Johnson, Ansari M Abbas, Dalai Sasmita
Department of Conservative Dentistry and Endodontics, Teerthanker Mahaveer Dental College and Research Centre, Moradabad, India.
Department of Prosthodontics and crown and bridge, Teerthanker Mahaveer Dental College and Research Centre, Moradabad, India.
J Oral Biol Craniofac Res. 2023 Mar-Apr;13(2):218-223. doi: 10.1016/j.jobcr.2023.01.007. Epub 2023 Jan 8.
Original Research.
To comparatively evaluate the effect of different premedication agents on the efficacy of 4% Articaine in teeth with symptomatic irreversible pulpitis.
The primary objective of our study is to evaluate the effect of premedication agents on efficacy of Articaine as an oral anesthetic. Our secondary objective is to comparatively evaluate the efficacy of Diclofenac patch, Ibuprofen tablet, Paracetamol tablet and Placebo as a premedication agent. Patients with 25-40 years age, no systemic disease, no history of medication for that complaint, with pain on Heft Parker Visual Analog Scale between 55 mm and 170 mm (VAS), no tenderness on percussion, cold test and EPT negative- Positive, giving proper consent, coming to the Department of Conservative Dentistry and Endodontics were allowed to participate. The exclusion criteria include the following- Non-vital teeth, pregnant and lactating women, allergic to Articaine and NSAIDs, active systemic disease, immune-compromised patients, taken analgesics in last 24 h, root fractures, restoration extending to pulp and periapical pathologies (except periodontal ligament widening).Preoperatively pain was recorded using Heft Parker VAS (Visual Analog Scale). Cold testing, palpation, percussion and EPT were carried out. 40 patients having symptomatic irreversible pulpitis were randomly divided into 4 groups: group 1 Placebo (n = 10), group 2-Diclofenac patch (n = 10), group-3 Ibuprofen tablets (n = 10), group 4-Paracetamol tablets (n = 10). After 1 h of premedication, all patients were administered IANB injection using 4% Articaine (Septanest with adrenaline 1/100000, Septodont, France) containing epinephrine 1:100000. 15 mins after administration of IANB, patients were asked about symptomatic numbness and was tested with Endo frost and EPT and Outcome was recorded. If lip numbness was present, Electric Pulp Testing and Cold Test give negative result then endodontic access opening was performed and pain was recorded using visual analog scale. The study was conducted for a period of 1.5 years.
During the access cavity preparation only 1 subject in the Group III reported pain while in other groups none of the subjects reported pain of any type. When the intergroup comparison was made of intensity of pain 15 min after LA and during access cavity preparation, the difference between the groups was statistically non-significant when analyzed using One Way ANOVA. The intragroup comparison between three time intervals revealed significant reduction in the pain scores from the pre-treatment levels in all the four groups.
The results of the study showed that there is no significant effect of different premedication agents on the efficacy of 4% Articaine in teeth with symptomatic irreversible pulpitis.
原创性研究。
比较评估不同术前用药对4%阿替卡因治疗有症状不可逆性牙髓炎疗效的影响。
本研究的主要目的是评估术前用药对阿替卡因作为口腔麻醉剂疗效的影响。次要目的是比较评估双氯芬酸贴片、布洛芬片、对乙酰氨基酚片和安慰剂作为术前用药的疗效。年龄在25至40岁之间、无全身疾病、无针对该主诉的用药史、Heft Parker视觉模拟量表(VAS)疼痛评分在55毫米至170毫米之间、叩诊无压痛、冷测和牙髓电活力测试(EPT)结果为阴性 - 阳性、给予适当知情同意且前来保守牙科与牙髓病科就诊的患者被允许参与。排除标准包括以下情况:非活髓牙、孕妇和哺乳期妇女、对阿替卡因和非甾体抗炎药过敏、活动性全身疾病、免疫功能低下患者、在过去24小时内服用过镇痛药、根折、修复体延伸至牙髓和根尖周病变(牙周膜增宽除外)。术前使用Heft Parker VAS(视觉模拟量表)记录疼痛情况。进行冷测、触诊、叩诊和EPT。40例有症状不可逆性牙髓炎患者被随机分为4组:第1组安慰剂组(n = 10),第2组双氯芬酸贴片组(n = 10),第3组布洛芬片剂组(n = 10),第4组对乙酰氨基酚片剂组(n = 10)。术前用药1小时后,所有患者使用含1:100000肾上腺素的4%阿替卡因(法国Septodont公司的Septanest含肾上腺素1/100000)进行下牙槽神经阻滞(IANB)注射。IANB注射后15分钟,询问患者有无症状性麻木,并用Endo frost和EPT进行测试,并记录结果。如果出现唇部麻木、牙髓电活力测试和冷测结果为阴性,则进行开髓,并使用视觉模拟量表记录疼痛情况。该研究进行了1.5年。
在开髓腔制备过程中,第III组仅1名受试者报告疼痛,而其他组均无任何类型的疼痛报告。当对局部麻醉(LA)后15分钟和开髓腔制备过程中的疼痛强度进行组间比较时,使用单因素方差分析(One Way ANOVA)分析,各组之间的差异无统计学意义。四个组内三个时间间隔的组内比较显示,所有四组的疼痛评分均较治疗前水平显著降低。
研究结果表明,不同术前用药对4%阿替卡因治疗有症状不可逆性牙髓炎的疗效无显著影响。